VIVUS, Inc. (VVUS) Extends Olive Branch, Follows With Fist

VIVUS, Inc. (NASDAQ:VVUS)Oh, what a difference a day makes.

On Saturday, VIVUS, Inc. (NASDAQ:VVUS) extended an olive branch to its largest shareholder and proxy-fight-adversary First Manhattan, offering to give the hedge fund three board seats whether First Manhattan won seats or not.

Trying to compromise is a good idea, one that I suggested a few weeks ago. Shares have nearly quadrupled since Biogen Idec Inc (NASDAQ:BIIB) ended its proxy fight with investor Carl Icahn by giving one of his nominees a seat on the board. I doubt Icahn’s nominee had that much influence on the success, given that there are 12 directors on the board. But not facing a proxy fight almost certainly helped Biogen Idec Inc (NASDAQ:BIIB) recruit CEO George Scangos, who arguably did have a lot to do with the success.

VIVUS, Inc. (NASDAQ:VVUS)’ niceness was short-lived, though, with the company claiming Sunday that it had reported First Manhattan to the SEC for “false and misleading statements.” The company didn’t actually say what First Manhattan had said except to point out that it was regarding statements about the recommendation of Institutional Shareholder Services, which recommended voting for three of First Manhattan’s nominees.

VIVUS, Inc. (NASDAQ:VVUS) used the issue as a reason (excuse) to delay Monday’s stockholders’ meeting until Thursday. First Manhattan countered suing VIVUS, asking the court to order the inspector of elections to certify the results based on the results that were prepared to be voted at the meeting on July 15.

I doubt the court will agree; for most annual meetings, shareholders have the right to vote at the meeting, so how can we know how shareholders would have ultimately voted if the meeting never occurred?

It seems clear from their actions, though, that both sides believe First Manhattan is leading the proxy fight. No one knows what’s next, but I doubt it’ll involve any compromises.

The real winner
The longer this drags on, the better it is for Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Eisai, which sell the obesity drug Belviq that competes directly with VIVUS, Inc. (NASDAQ:VVUS)’ Qsymia. With management and employees distracted by the proxy fight, I doubt marketing of the drug is firing on all cylinders.

If First Manhattan wins, the hedge fund has made it clear it plans to replace CEO Leland Wilson with Anthony Zook, the former president of MedImmune. Even if the switch can take place fairly quickly, it’ll take time to get the new strategy implemented.

Depending on how well VIVUS, Inc. (NASDAQ:VVUS) recovers from the turmoil, the proxy fight could even benefit Orexigen Therapeutics, Inc. (NASDAQ:OREX), which has an obesity drug that could be on the market next year.

If VIVUS, Inc. (NASDAQ:VVUS) somehow pulls a come-from-behind victory, I expect that shares might drop substantially since it seems clear there’s a sizable shareholder base looking for a change.

Investors might also vote in some, but not all, of First Manhattan’s nominees, which would seem to be the worst outcome for VIVUS and therefore the best for Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Orexigen Therapeutics, Inc. (NASDAQ:OREX). Internal boardroom fighting would certainly hinder the long-term prospects for Qsymia.

The article VIVUS Extends Olive Branch, Follows With Fist originally appeared on Fool.com and is written by Brian Orelli.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 44 percentage points in 21 months Learn how!

Lists

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

12 Most Expensive Countries for Foreign Students

Top 30 Most Influential Women in the World

Top 20 Most Expensive New Year Eve Shows

Top 5 Best Vocational Careers

Top 10 Jobs for 2014 by Salary Gain (Predictions)

Top 5 Digital Trends for 2014

Top 6 Things You Can Do To Increase Your Productivity

Top 9 Trending Smartphones in 2013

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!